Since 2002, Lohmann has performed all manufacturing, marketing and distribution activities for Celldex's marketed Megan® Vac 1 and Megan Egg poultry vaccines and has paid Celldex product royalties. Financial terms of the transaction were not disclosed.

"We continue to focus strategically on our Precision Targeted Immunotherapy Platform and the clinical and preclinical programs that are emerging from this novel approach to immunotherapy," stated Anthony S. Marucci, President and Chief Executive Officer of Celldex Therapeutics, Inc.

"As a result of our focus on human health care, we are pleased to have found an appropriate home for these assets with Lohmann, a leader in the poultry industry in North America, with an extensive product line of vaccines and related products."

"We are excited to have completed this transaction with Celldex Therapeutics," said David Zacek, President and Chief Executive Officer of Lohmann Animal Health International. "Megan Vac 1 and Megan Egg will remain important vaccines within our growing poultry products business. Lohmann is committed to building a powerful force in the avian health industry."

Celldex Therapeutics is an integrated biopharmaceutical company that applies its comprehensive Precision Targeted Immunotherapy Platform to generate a pipeline of candidates to treat cancer and other difficult-to-treat diseases. Celldex's immunotherapy platform includes a complementary portfolio of monoclonal antibodies, antibody-targeted vaccines and immunomodulators to create novel disease-specific drug candidates.

Lohmann Animal Health International is a leading manufacturer and supplier of poultry biologics for the US and international vaccine markets. Based in Winslow, Maine, Lohmann is a member of the PHW Group, which comprises 40 companies that produce poultry health products for the global market.